U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H22N4O2
Molecular Weight 278.3501
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NP-51

SMILES

OC(CONC(=N)C1=CC=CN=C1)CN2CCCCC2

InChI

InChIKey=MVLOQULXIYSERZ-UHFFFAOYSA-N
InChI=1S/C14H22N4O2/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17)

HIDE SMILES / InChI

Molecular Formula C14H22N4O2
Molecular Weight 278.3501
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

N-Gene Research Laboratories is developing BGP-15 (NP-51), a small molecule, orally available, indirect Jun kinase (JNK) inhibitor and insulin sensitiser, for glycaemic control in patients with type-2 diabetes mellitus, and as an adjunct treatment for insulin resistance due to antipsychotics or obesity. In March 2002, N-Gene Research Laboratories granted Allos Therapeutics an exclusive license to its intellectual property surrounding BGP 15 in the US. BGP-15 has previously been used in clinical trials for the treatment of skeletal muscle pathology associated with Type 2 Diabetes (through insulin sensitization), Duchenne Muscular Dystrophy (DMD) and heart failure (through anti-inflammatory and anti-fibrotic mechanisms). Via its action as a modulator of the cytoprotective response to cellularstress, and specifically as a poly (ADP-ribose) polymerase (PARP) inhibitor, heat shock protein-inducer, membrane lipid therapeutic and an antioxidant inducer, BGP-15 has previously been shown to protect against skeletal muscle dysfunction, damage and wasting.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Poly (ADP-ribose) polymerase
120.0 µM [IC50]
PubMed

PubMed

TitleDatePubMed
BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase.
2000 Apr 15
BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle.
2016 Dec
BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice.
2017
BGP-15 improves contractile function of regenerating soleus muscle.
2018 Apr

Sample Use Guides

The efficacy and safety of BGP-15 were compared with placebo in insulin-resistant patients in a 28-day dose-ranging study. Forty-seven nondiabetic patients with impaired glucose tolerance were randomly assigned to 4 weeks of treatment with 200 or 400 mg of BGP-15 or placebo. BGP-15 at 200 or 400 mg significantly improved insulin sensitivity in insulin-resistant, nondiabetic patients during treatment compared to placebo and was safe and well-tolerated.
Route of Administration: Oral
Kinetic analysis showed a mixed-type (noncompetitive) inhibition by BGP-15 of nuclear poly(ADP-ribose) polymerase (PARP) with a K(i) = 57 +/- 6 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:27:31 GMT 2023
Edited
by admin
on Sat Dec 16 09:27:31 GMT 2023
Record UNII
28ENT76V8K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NP-51
Common Name English
BGP-15 FREE BASE
Common Name English
(±)-O-(3-PIPERIDINO-2-HYDROXY-1-PROPYL)NICOTINIC ACID AMIDOXIME
Systematic Name English
3-PYRIDINECARBOXIMIDAMIDE, N-(2-HYDROXY-3-(1-PIPERIDINYL)PROPOXY)-
Systematic Name English
Code System Code Type Description
SMS_ID
300000013628
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
PRIMARY
CAS
79104-68-0
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
SUPERSEDED
EPA CompTox
DTXSID201170597
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
PRIMARY
FDA UNII
28ENT76V8K
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
PRIMARY
CAS
66611-38-9
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
PRIMARY
PUBCHEM
9817104
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
PRIMARY
CAS
937402-06-7
Created by admin on Sat Dec 16 09:27:31 GMT 2023 , Edited by admin on Sat Dec 16 09:27:31 GMT 2023
SUPERSEDED
Related Record Type Details
ACTIVE MOIETY